Press releases
- New Study Published on the Impact of Pharmaceutical Support Programs on Persistence with Clozapine Treatment
- HLS Therapeutics Announces Q1 2024 Financial Results
- HLS Therapeutics to Host Q1 Fiscal 2024 Financial Results Conference Call
- HLS Therapeutics to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups
- HLS Therapeutics Announces Fiscal 2023 Financial Results
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 31.89m |
Free float | 31.77m |
P/E (TTM) | -- |
Market cap | 118.62m CAD |
EPS (TTM) | -1.18 CAD |
Annual div (ADY) | -- |
---|---|
Annual div yield (ADY) | -- |
Div ex-date | Apr 27 2023 |
Div pay-date | Jun 15 2023 |
Data delayed at least 15 minutes.
More ▼